Du är här


Swedish Orphan Biovitrum AB (publ): Sobi appoints Kirsti Gjellan as Senior Vice President Manufacturing Operations

Swedish Orphan Biovitrum AB (publ) (Sobi) today announced that Kirsti Gjellan
has been appointed Senior Vice President Manufacturing Operations. Gjellan
joins Sobi from global pharmaceutical company Pfizer where she has been
Managing Director and Site Leader at the Strängnäs site for Pfizer Health AB
as well as Member of the Pfizer Health AB Board.

A Ph.D. in Pharmaceutical Technology, Kirsti Gjellan brings a strong track
record from leading positions within both Pfizer and AstraZeneca. She has
experience from working both with quality and manufacturing and her
achievements have been both internally and externally awarded. In 2006
Gjellan was honoured with Pfizer's John Mitchell Quality Award and in 2013
she was named Swedish Pharma Profile of the Year.

"We are delighted to welcome Kirsti to Sobi", said Geoffrey McDonough,
President and CEO at Sobi. "Kirsti will continue to build on the legacy of
our biologics manufacturing organisation, and to prepare us for our future
products for patients with rare diseases. Kirsti will also be a great
addition to our senior leadership team."

"I'm very much looking forward to my new role and to, together with Sobi's
Leadership team and all new colleagues, work to bring new therapies for rare
diseases to patients who don't have access to medicines today," said Kirsti

Kirsti Gjellan will join Sobi in September 2014. She takes over after Lena
Nyström who will retire later this year.


About Sobi

Sobi is an international specialty healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on Inflammation and Genetic diseases, with two late stage biological
development projects within Haemophilia. We also market a portfolio of
specialty and rare disease products for partner companies. Sobi is a pioneer
in biotechnology with world-class capabilities in protein biochemistry and
biologics manufacturing. In 2013, Sobi had total revenues of SEK 2.2 billion
($334 M) and about 550 employees. The share (STO: SOBI) is listed on NASDAQ
OMX Stockholm. More information is available atwww.sobi.com.

For more information - not for publication
|Media relations Investor relations |
|Oskar Bosson, Head of Communications Jörgen Winroth, Vice President, Head of Investor Relations |
|T: +46 70 410 71 80 T: +1 347-224-0819, +1 212-579-0506, +46 8 697 2135 |
|oskar.bosson@sobi.com jorgen.winroth@sobi.com |

The above information was released for public distribution on 26 May 2014, at
15:30 CET.

Sobi appoints Kirsti Gjellan as Senior Vice President Manufacturing Op


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.